프로톤 펌프 저해제 시장 : 세계 산업 규모, 점유율, 동향, 기회 및 예측 - 약제 유형별, 질환별, 용도별, 지역별, 경쟁별 세분화(2020-2030년)

The Global Proton Pump Inhibitors Market, valued at USD 3.15 Billion in 2024, is projected to experience a CAGR of 4.87% to reach USD 4.19 Billion by 2030. Proton Pump Inhibitors are a class of pharmaceutical compounds designed to reduce gastric acid secretion by irreversibly blocking the hydrogen/potassium adenosine triphosphatase enzyme system of gastric parietal cells. The global market for these agents is driven by the increasing worldwide prevalence of gastroesophageal reflux disease, peptic ulcer disease, and other acid-related gastrointestinal disorders, coupled with an expanding geriatric population more susceptible to such conditions.

Key Market Drivers

The global Proton Pump Inhibitors market experiences substantial growth, primarily propelled by the escalating prevalence of gastroesophageal reflux disease and peptic ulcers, alongside the expanding geriatric population's increased susceptibility to gastrointestinal disorders. The widespread occurrence of conditions such as GERD and peptic ulcers forms the foundational demand for PPIs, given their efficacy in managing acid-related symptoms and promoting healing. According to Frontiers, in Global, regional, and national burden of gastroesophageal reflux disease (1990-2021): age-period-cohort analysis and Bayesian projections, published in 2023, global GERD prevalence reached 825.6 million cases in 2021, underscoring the significant patient pool requiring effective acid suppression therapies.

Key Market Challenges

The long-term safety profile of Proton Pump Inhibitors presents a notable challenge to market expansion. Growing clinical evidence and heightened regulatory scrutiny regarding potential adverse effects linked to prolonged use are increasingly influencing prescribing patterns among healthcare providers. This necessitates more cautious consideration during patient consultations and can lead to reduced initiation of long-term PPI therapy. Consequently, patient adherence may also be impacted, as individuals become more aware of reported risks, potentially leading to earlier discontinuation of treatment. These dynamics directly impede the sustained growth of the Global Proton Pump Inhibitors Market by tempering the volume of new prescriptions and the duration of existing ones.

Key Market Trends

Innovation in advanced PPI formulations and delivery represents a crucial trend, driven by the pharmaceutical industry's continuous efforts to enhance therapeutic profiles, improve patient adherence, and mitigate potential long-term side effects. This focus includes developing novel drug delivery systems and formulations that offer faster onset of action or prolonged efficacy. For example, Takeda Pharmaceutical Company Limited, in its first-quarter fiscal year 2025 results announced in July 2025, reaffirmed its commitment to discovering and delivering life-transforming treatments in its core therapeutic areas, explicitly including gastrointestinal and inflammation, highlighting ongoing innovation in this critical space.

Key Market Players

• Bayer AG
• AstraZeneca PLC
• Pfizer, Inc.
• Eli Lilly and Co Ltd
• Teva Pharmaceutical Industries Ltd
• Cadila Pharmaceuticals Ltd
• Johnson & Johnson
• Takeda Pharmaceutical Co Ltd
• Eisai Co Ltd

Report Scope:

In this report, the Global Proton Pump Inhibitors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Proton Pump Inhibitors Market, By Drug Type:

• Pantoprazole
• Omeprazole
• Lansoprazole Esomeprazole Rabeprazole
• Dexlansoprazole Others

Proton Pump Inhibitors Market, By Disease Allocation:

• Ulcers
• Gastroesophageal Reflux Disease
• Others

Proton Pump Inhibitors Market, By Application:

• Hospitals
• Clinic
• Others

Proton Pump Inhibitors Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Proton Pump Inhibitors Market.

Available Customizations:

Global Proton Pump Inhibitors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Proton Pump Inhibitors Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Pantoprazole, Omeprazole, Lansoprazole Esomeprazole Rabeprazole, Dexlansoprazole, Others)
  • 5.2.2. By Disease Allocation (Ulcers, Gastroesophageal Reflux Disease, Others)
  • 5.2.3. By Application (Hospitals, Clinic, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Proton Pump Inhibitors Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Disease Allocation
  • 6.2.3. By Application
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Proton Pump Inhibitors Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Disease Allocation
      • 6.3.1.2.3. By Application
  • 6.3.2. Canada Proton Pump Inhibitors Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Disease Allocation
      • 6.3.2.2.3. By Application
  • 6.3.3. Mexico Proton Pump Inhibitors Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Disease Allocation
      • 6.3.3.2.3. By Application

7. Europe Proton Pump Inhibitors Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Disease Allocation
  • 7.2.3. By Application
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Proton Pump Inhibitors Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Disease Allocation
      • 7.3.1.2.3. By Application
  • 7.3.2. France Proton Pump Inhibitors Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Disease Allocation
      • 7.3.2.2.3. By Application
  • 7.3.3. United Kingdom Proton Pump Inhibitors Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Disease Allocation
      • 7.3.3.2.3. By Application
  • 7.3.4. Italy Proton Pump Inhibitors Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Disease Allocation
      • 7.3.4.2.3. By Application
  • 7.3.5. Spain Proton Pump Inhibitors Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Disease Allocation
      • 7.3.5.2.3. By Application

8. Asia Pacific Proton Pump Inhibitors Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Disease Allocation
  • 8.2.3. By Application
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Proton Pump Inhibitors Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Disease Allocation
      • 8.3.1.2.3. By Application
  • 8.3.2. India Proton Pump Inhibitors Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Disease Allocation
      • 8.3.2.2.3. By Application
  • 8.3.3. Japan Proton Pump Inhibitors Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Disease Allocation
      • 8.3.3.2.3. By Application
  • 8.3.4. South Korea Proton Pump Inhibitors Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Disease Allocation
      • 8.3.4.2.3. By Application
  • 8.3.5. Australia Proton Pump Inhibitors Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Disease Allocation
      • 8.3.5.2.3. By Application

9. Middle East & Africa Proton Pump Inhibitors Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Disease Allocation
  • 9.2.3. By Application
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Proton Pump Inhibitors Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Disease Allocation
      • 9.3.1.2.3. By Application
  • 9.3.2. UAE Proton Pump Inhibitors Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Disease Allocation
      • 9.3.2.2.3. By Application
  • 9.3.3. South Africa Proton Pump Inhibitors Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Disease Allocation
      • 9.3.3.2.3. By Application

10. South America Proton Pump Inhibitors Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Disease Allocation
  • 10.2.3. By Application
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Proton Pump Inhibitors Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Disease Allocation
      • 10.3.1.2.3. By Application
  • 10.3.2. Colombia Proton Pump Inhibitors Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Disease Allocation
      • 10.3.2.2.3. By Application
  • 10.3.3. Argentina Proton Pump Inhibitors Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Disease Allocation
      • 10.3.3.2.3. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Proton Pump Inhibitors Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bayer AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. AstraZeneca PLC
• 15.3. Pfizer, Inc.
• 15.4. Eli Lilly and Co Ltd
• 15.5. Teva Pharmaceutical Industries Ltd
• 15.6. Cadila Pharmaceuticals Ltd
• 15.7. Johnson & Johnson
• 15.8. Takeda Pharmaceutical Co Ltd
• 15.9. Eisai Co Ltd

16. Strategic Recommendations

17. About Us & Disclaimer